Abstract
There are 500,000 new cases of cervical cancer every year, and about 84% of them occur in developing countries. Fifty-six percent to ninety percent of these women present late with FIGO stage III or IV. All cervical cancers are attributable to genital Human Papilloma Virus (HPV) infection, and the introduction of HPV vaccine has raised the potential for significant reduction in worldwide incidence of HPV infection and cervical cancer. The HPV vaccines are bivalent (active against HPV 16 and 18) or quarivalent (active against HPV 6, 11, 16 and 18). HPV type 16 and 18 accounts for 75% of cervical cancer. In HPV naïve women, both vaccines are over 99% effective in preventing precancerous lesions and subsequently cervical cancer associated with HPV type 16 and 18. The objective of HPV immunisation programme is to provide three doses of the vaccine to girls before they reach the age when the risk of HPV infection increases, but vaccination programmes are very low and variable in sub-Saharan Africa. It is estimated that vaccination of 58 million 12-year old girls before the start of sexual activity worldwide will prevent 690,000 cases and 420,000 deaths related to cervical cancer at a cost of US$4 billion. Seventy percent of cancers prevented, and 75% of deaths, will be in low or lower middle income countries. Screening is essential, as early treatment of pre-cancerous lesions prevents up to 80% of cervical cancers in countries where screening is routine. However, screening implementation and utilisation is challenging in Africa because of poor infrastructure, long travel distances, lack of trained medical personnel, inadequate record keeping and delayed testing. Therefore, the WHO approved strategy for cervical screening in low resource countries is visual inspection with acetic acid (VIA) or with Lugol’s iodine (VILI). Despite their limited specificity both VIA and VILI are useful screening tools for low-resource settings because they are economical, and they provide immediate results. Research is going on in SSA about the feasibility and utility of HPV-DNA testing for cervical cancer screening, but in the short to medium term, HPV vaccination and VIA secondary screening will save many lives in SSA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adefuye PO, Broutet NJ, de Sanjose S, Denny LA. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa. Vaccine. 2013;31(S5):F53–39.
American Cancer Society. Infections that can lead to cancer. 2016. http://www.cancer.org/acs/groups/cid/documents/webcontent/002782-pdf.pdf
Aniebue PN, Aniebue UU. Awareness and practice of cervical cancer screening among female undergraduate students in a Nigerian university. J Cancer Educ. 2010;25(1):106–8.
Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003a;89:101–5.
Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003b;88(1):63–73.
Clifford GM, Rana RK, Franceschi S, et al. Human papilloma genotype distribution in low-grade cervical lesions: comparison by geographical region and with cervical cancer. Cancer Epidemiol Biomark Prev. 2005;14(5):1157–64.
Denny L, Sankaranarayanan R, De Vuyst H, et al. Recommendations for cervical cancer prevention is sub-Saharan Africa. Vaccine. 2013;31(S5):F73–4.
Dim CC, Ekwe E, Madubuko T, et al. Improved awareness of Pap smear may not affect its use in Nigeria: a case study of female medical practitioners in Enugu, Southeastern Nigeria. Trans R Soc Trop Med Hyg. 2009;103(8):852–4.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 GLOBOCAN 2012 v1.1.
Finocchario-Kessler S, Wexler C, Maloba M, et al. Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective. BMC Womens Health. 2016;16(1):29.
Franco EL, Harper DM. Vaccination against human papilloma virus infection: a new paradigm in cervical cancer control. Vaccine. 2005;23(17–18):2388–94.
Herrero R, Franceschi S. Vaccination. In: Stewart BW, Wild C, editors. World cancer report. Lyon: International Agency for Research on Cancer; 2014. p. 314–21.
IARC (International Agency for Research on Cancer). GLOBOCAN. 2012. http://globocan.iarc.fr/Pages/online.aspx
Idowu A, Olowookere SA, Fagbemi AT, Ogunlaja OA. Determinants of cervical cancer screening uptake among women in Ilorin, North Central Nigeria: a community-based study. J Cancer Epidemiol. 2016;2016:6469240. doi:10.1155/2016/6469240. Epub 2016 Jan 6.
Jit M, Brisson M, Portnay A, Hutubessy R. Cost-effectiveness of female human papilloma vaccination in 179 countries: a PRIME modelling study. Lancet Glob Health. 2014;2:e406–14.
Kabir M, Iliyasu Z, Abubakar IS, Mahboob S. Awareness and practice of cervical cancer screening among female health professionals in Murtala Mohammed Specialist Hospital. Niger Postgrad Med J. 2005;12(2):179–82.
Kim JJ, Campos NG, O’Shea M, et al. Model-based impact and cost-effectiveness of cervical prevention in sub-Saharan Africa. Vaccine. 2013;31(Suppl 5):F60–72.
Lancet Editorial. HPV vaccination: a decade on. Lancet. 2016;388(10043):438.
Lince-Deroche N, Phiri J, Michelow P, et al. Cost and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa. PLoS One. 2015;10(11):e0141969.
Madeleine MM, Daling JR, Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst. 1997;89:1516–23.
Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278–85.
Musa J, Nankat J, Chad J, et al. Cervical cancer survival in a resource-limited setting-North Central Nigeria. Infect Agent Cancer. 2016;11:15. doi:10.1186/s13027-016-0062-0. Published online 2016 Mar 24.
National Institute for Health and Clinical excellence (NICE) Guidance on the use of liquid-based cytology for cervical screening. Technology appraisal guidance [TA69] 2003.
Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. The Lancet. 2004;364(9430):249–56.
Plummer M, De Martel C, Ferlay J et al. Global burden of cancers attributable to infections in 2012: A synthentic analysis. Lancet Glob Health. 2016. http://dx.doi.org/10.1016/S2214-109X(16)30143-7
Schiller W. Leucoplakia and cancer of the cervix. Am J Obstet Gynecol. 1938;35:17.
Singh S, Badaya S. Tele-cytology: an innovative approach for cervical cancer screening in resource-poor settings. J Cancer Res Ther. 2016;12:481–5.
Sotlar K, Diemer D, Dethleffs A, et al. Detection and typing of human papillomavirus by E6 nested multiplex PCR. J Clin Microbiol. 2004;42:3176–84.
Sub-Saharan Africa Cervical Cancer Working Group. Model HPV vaccine recommendations for sub-Saharan Africa. Clin Mother Child Health. 2009;6(1):1047–52.
Syrjänen K, Syrjänen S. Papillomavirus infections. In:Human pathology. Chichester: Wiley; 2000. p. 11–46.
Von Krogh G. Management of anogenital warts (condylomata acuminate). Eur J Dermatol. 2001;11(6):598–603.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Ogueh, O., Adedeji, O.A. (2017). The Prevention of Cervical Cancer. In: Adedeji, O. (eds) Cancer in Sub-Saharan Africa. Springer, Cham. https://doi.org/10.1007/978-3-319-52554-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-52554-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52553-2
Online ISBN: 978-3-319-52554-9
eBook Packages: MedicineMedicine (R0)